Journal article
Antibody landscapes after influenza virus infection or vaccination
JM Fonville, SH Wilks, SL James, A Fox, M Ventresca, M Aban, L Xue, TC Jones, NMH Le, QT Pham, ND Tran, Y Wong, A Mosterin, LC Katzelnick, D Labonte, TT Le, G van der Net, E Skepner, CA Russell, TD Kaplan Show all
SCIENCE | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2014
Abstract
We introduce the antibody landscape, a method for the quantitative analysis of antibody-mediated immunity to antigenically variable pathogens, achieved by accounting for antigenic variation among pathogen strains. We generated antibody landscapes to study immune profiles covering 43 years of influenza A/H3N2 virus evolution for 69 individuals monitored for infection over 6 years and for 225 individuals pre- and postvaccination. Upon infection and vaccination, titers increased broadly, including previously encountered viruses far beyond the extent of cross-reactivity observed after a primary infection. We explored implications for vaccination and found that the use of an antigenically advance..
View full abstractGrants
Awarded by Medical Research Council Fellowship
Awarded by Royal Society University Research Fellowship
Awarded by National Institute of Allergy and Infectious Diseases-NIH Centers of Excellence for Influenza Research and Surveillance contracts
Awarded by Nederlandse Organisatie voor Wetenschappelijk Onderzoek VICI grant
Awarded by European Union
Awarded by Human Frontier Science Program grant
Awarded by Wellcome Trust
Awarded by NIH Director's Pioneer Award
Awarded by MRC
Awarded by Medical Research Council
Funding Acknowledgements
We thank R. Bodewes, J. Bryant, D. Burke, N. Lewis, E. Selkov, B. Muhlemann, G. de Mutsert, and F. Pistoor. We also thank the staff of the Ha Nam Provincial Preventive Medicine Centre, the Hamlet health workers, and the National Institute for Hygiene and Epidemiology, Vietnam, for their support in conducting the fieldwork. We are indebted to the cooperation of the Ha Nam cohort and vaccine study participants. J.M.F. is supported by a Medical Research Council Fellowship (MR/K021885/1) and a Junior Research Fellowship from Homerton College, L. C. K. by the Gates-Cambridge Scholarship and the NIH Oxford-Cambridge Scholars program, and C. A. R. by a Royal Society University Research Fellowship (RG55423). We acknowledge the National Institute of Allergy and Infectious Diseases-NIH Centers of Excellence for Influenza Research and Surveillance contracts HHSN266200700010C and HHSN272201400008C, Nederlandse Organisatie voor Wetenschappelijk Onderzoek VICI grant 91896613, the European Union FP7 programs EMPERIE (223498) and ANTIGONE (278976), Human Frontier Science Program grant P0050/2008, the Wellcome Trust (WT087982MA), and NIH Director's Pioneer Award DP1-OD000490-01. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian government Department of Health. A.D.M.E.O. (as Chief Scientific Officer of Viroclinics Biosciences BV) has advisory affiliations with GlaxoSmithKline, Novartis, and Roche. Sequences of the influenza viruses used in this study are available in GenBank with accession numbers: KM821278 to KM821358. Erasmus Medical Center (Rotterdam, the Netherlands) requires a materials transfer agreement for sharing viruses and antisera.